Edition:
United Kingdom

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

1.01USD
8:59pm GMT
Change (% chg)

$-0.01 (-0.98%)
Prev Close
$1.02
Open
$1.03
Day's High
$1.04
Day's Low
$0.98
Volume
338,687
Avg. Vol
165,430
52-wk High
$6.58
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

James Flynn Reports 6.57 Percent Passive Stake In Axovant Sciences Ltd
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Deerfield Management L.P::JAMES FLYNN REPORTS 6.57 PERCENT PASSIVE STAKE IN AXOVANT SCIENCES LTD AS OF DECEMBER 18 - SEC FILING.  Full Article

Axovant Sciences Says Public Offering Of 30.0 Mln Common Shares Priced At $1 Per Share
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES ANNOUNCES PRICING OF $30 MILLION PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 30.0 MILLION COMMON SHARES PRICED AT $1.00PER SHARE.  Full Article

Axovant Sciences announces public offering of common shares
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES ANNOUNCES PUBLIC OFFERING OF COMMON SHARES.  Full Article

Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD For Parkinson’S Disease
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Axovant Sciences Ltd ::AXOVANT ANNOUNCES FEEDBACK FROM FDA MEETING REGARDING AXO-LENTI-PD FOR PARKINSON’S DISEASE AND PROGRESS IN ONGOING SUNRISE-PD PHASE 2 CLINICAL TRIAL.AXOVANT SCIENCES LTD - CONFIRMED WITH FDA THAT PROPOSED CURRENT MANUFACTURING PROCESS AND QUALITY CONTROL TESTING IS ADEQUATE FOR CLINICAL PROGRAM.AXOVANT SCIENCES LTD - DOSED SECOND PATIENT IN SUNRISE-PD PHASE 2 CLINICAL TRIAL OF AXO-LENTI-PD IN NOVEMBER 2018, WITH DATA EXPECTED IN MARCH 2019.AXOVANT-MEETING WITH FDA CONFIRM STUDIES CONDUCTED USING FIRST GENERATION PROSAVIN BE CONSIDERED PART OF SINGLE DEVELOPMENT PROGRAM WITH AXO-LENTI-PD.AXOVANT SCIENCES LTD - SUNRISE-PD STUDY IS ADVANCING AS PLANNED WITH DOSING OF SECOND PATIENT IN NOVEMBER 2018.AXOVANT - BOTH PATIENTS TOLERATED SURGICAL PROCEDURE WELL & WERE DISCHARGED HOME WITH NO SERIOUS ADVERSE EVENTS OBSERVED IN SUNRISE-PD STUDY.AXOVANT SCIENCES LTD - ENCOURAGED TO RETURN FOR AN END-OF-PHASE 2 MEETING AFTER COMPLETION OF ONGOING SUNRISE-PD STUDY.  Full Article

Axovant Sciences Says Frank Torti Appointed Chairman Of The Board
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Axovant Sciences Ltd ::SAYS FRANK TORTI APPOINTED CHAIRMAN OF THE BOARD.AXOVANT SCIENCES - EFFECTIVE SEPTEMBER 26, VIVEK RAMASWAMY RESIGNED AS A MEMBER AND CHAIRPERSON OF BOARD.  Full Article

Axovant Sciences Says Entered Sales Agreement With Cowen And Co
Friday, 22 Jun 2018 

June 22 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES LTD - ON JUNE 22, 2018, CO ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING.AXOVANT SCIENCES LTD - AGREEMENT TO SELL CO'S COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME.  Full Article

Axovant Says Gavin Corcoran, Chief Medical Officer Of Allergan, To Join Co As EVP Of R&D
Tuesday, 29 May 2018 

May 29 (Reuters) - Axovant Sciences Ltd ::AXOVANT STRENGTHENS MANAGEMENT TEAM AND COMPLETES ORGANIZATIONAL RESTRUCTURING IN PREPARATION FOR PIPELINE EXPANSION.AXOVANT SCIENCES LTD - AS PART OF RESTRUCTURING PLAN, INTERNAL HEADCOUNT HAS DECREASED BY APPROXIMATELY 43%.AXOVANT SCIENCES LTD - GAVIN CORCORAN, CURRENT CHIEF MEDICAL OFFICER OF ALLERGAN PLC, TO JOIN AXOVANT AS EVP OF RESEARCH AND DEVELOPMENT.  Full Article

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Wednesday, 6 Dec 2017 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article

UPDATE 1-Moderna, largest biotech to go public, fails to impress in market debut

Dec 7 Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.